Follow
'The authors evaluated 29 anticancer drugs that received a first marketing authorisation for 32 separate cancer indications in 2017-19. Most (23/32, 72%) of the indications were not associated with any direct survival benefit; instead, approval was on the basis of surrogate outcomes, such as progression-free survival or tumour response.'
